While GW 4064 (a FXR agonist) inhibited SARS-CoV-2 replication in vitro (Fig. 5e and Supplementary Fig. 29), the GW 4064 treatment significantly improved survival of hamsters following SARS-CoV-2 B.1.1.7 (alpha) variant infection without affecting the virus titer at early time points (Fig. 5f, g and Supplementary Fig. 30). This evidence concerns the gene NR1H4 and infection.